간편하게 보는 뉴스는 유니콘뉴스
Boston Oncology and King Fahd Medical City (KFMC) Partner to Advance Localized Cell & Gene Therapy in Saudi Arabia

· 등록일 Aug. 01, 2024 15:30

· 업데이트일 2024-08-02 00:00:19

CAMBRIDGE, MASS. & RIYADH, SAUDI ARABIA--(Business Wire / Korea Newswire)--In a landmark initiative poised to transform healthcare in the Kingdom of Saudi Arabia, Boston Oncology and King Fahd Medical City (KFMC) have signed a Letter of Intent to collaborate on the localization of Cell & Gene Therapy.

Representatives from Boston Oncology and King Fahd Medical City (KFMC), along with His Excellency Eng. Abdulaziz AlRamaih, Deputy Minister of Health for Planning and Development, at the signing ceremony for the partnership to advance localized Cell & Gene Therapy in Saudi Arabia. (Photo: Business Wire) The signing ceremony, attended by His Excellency Eng. Abdulaziz AlRamaih, Deputy Minister of Health for Planning and Development, marks a significant step forward in advancing the Kingdom’s medical capabilities and achieving the ambitious goals set forth in Vision 2030.

A Milestone in Healthcare Transformation

Dr. Fahad Al-Ghofaili, KFMC CEO, expressed his enthusiasm: “Localizing Cell & Gene Therapy in KFMC is an important step to increase local capabilities in advanced treatments and medical technologies, contributing to the goals of the Healthcare Transformation Project.” [Translated from Arabic]

Impact for Patients

Boston Oncology, renowned for its customer-centered model, brings extensive expertise in localizing technology. Laser-focused on the real-world needs of patients and hospitals, Boston Oncology is positioned to provide cutting-edge technologies and Cell & Gene Therapies through this partnership. This collaboration will establish a local treatment option, relieving bottlenecks in therapy provision and improving patient outcomes. The resulting Research & Development and clinical trials will significantly contribute to innovative advancements in the healthcare sector of Saudi Arabia.

Dr. Abdullah Baaj, CEO of Boston Oncology, described the partnership: “KFMC brings world-class clinicians and infrastructure, making it a destination for patients throughout the region. Joining forces to localize Cell & Gene Therapy is a transformative step towards our mission to impact the lives of one billion patients.”

About Boston Oncology Cell & Gene Therapy

Boston Oncology is an innovative life science company with a mission to impact the lives of one billion patients by 2030. With corporate headquarters in Cambridge, Massachusetts, and operations throughout the world, the company is focused on bringing patient-centered solutions and advanced treatment modalities to growing markets. Its new Cell & Gene Therapy entity establishes a fully localized offering to deliver personalized treatments that address the unique genetic profiles of patients. By partnering with leading medical institutions and leveraging leading-edge technologies, Boston Oncology CGT is expanding the company’s legacy of transformative advancements in healthcare.

Learn more at https://bostononcology.com/.

About King Fahd Medical City

King Fahad Medical City (KFMC) in Riyadh, Saudi Arabia, stands as one of the largest and most rapidly expanding medical complexes in the Middle East, with a capacity of 1,200 beds. Operating within the second health cluster, KFMC consists of four hospitals and four specialized medical centers, offering comprehensive healthcare services. Known for its advanced medical technologies and high standard of care, KFMC serves over 30,000 inpatients and 500,000 outpatients annually. The institution is committed to excellence in clinical services, medical education, research, and continuous improvement in healthcare.

Learn more at https://www.kfmc.med.sa/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240731424463/en/

Website: https://bostononcology.com/ Contact Boston Oncology
Public Relations
[email protected]
This news is a press release provided by Boston Oncology. Korea Newswire follows these editorial guidelines. Boston Oncology News ReleasesSubscribeRSS 보스턴 온콜로지-킹 파흐드 메디컬 시티, 사우디에서 세포·유전자 치료 현지화의 발전 위해 파트너십 체결 보스턴 온콜로지(Boston Oncology)와 킹 파흐드 메디컬 시티(King Fahd Medical City, KFMC)가 세포 및 유전자 치료의 현지화에 대한 협력 의향서에 서명하면서 사우디아라비아의 의료 혁신을 위한 기념비적 이니셔티브를 시작했다. 압둘라지즈 알라마이흐 보건부 기획개발 차관(His Excellency Eng. Abdulazi... 8월 1일 15:30 More News Health Biotechnology Pharmaceutical Alliance Overseas Boston Oncology All News Releases 
인기 기사01.13 17시 기준
안양--(뉴스와이어)--국내 냉동피자 시장 1위 오뚜기가 글로벌 핫소스 브랜드 타바스코와의 협업해, 타바스코 소스를 베이스로 활용해 매콤새콤한 맛을 살린 윈터에디션 ‘타바스코 피자’ 2종을 한정 출시했다. 오뚜기, 윈터에디션...
서울--(뉴스와이어)--사건사고를 겪은 이들이 신속하고 효율적으로 전문가의 도움을 받을 수 있는 사건사고 종합 솔루션 플랫폼 ‘골고루팀’(골고루보상, 대표 유태석)은 지난 10일 한양방협진 참잘함한방병원과 MOU를 체결했다고 22일 밝혔다. 사건사고TV...
서울--(뉴스와이어)--초등 전과목 온라인 학습 서비스 플랫폼 ‘미래엔초코’를 출시한 교과서 발행 부수 1위 기업 미래엔이 예스24와 함께 ‘예스24 X 미래엔초코 전국 초등 학부모 강연회’를 진행한다. 미래엔,...
노스브룩, 일리노이--(Business Wire / 뉴스와이어)--응용 안전 과학 분야의 글로벌 리더인 UL 솔루션즈(NYSE: ULS)가 자동차 제조업체와 공급업체가 다양한 재료의 성능을 안전하게 비교하여 전기자동차(EV) 배터리 안전성을 향상시킬 수 있도록 지원하기 위해 일본 미에현 이세에 새로운 배터리...
서울--(뉴스와이어)--클린 바디케어 브랜드 ‘데미플로(de mi flor)’가 배우 이이담을 브랜드 전속 모델로 발탁했다고 3일 밝혔다. 클린 바디케어 브랜드 ‘데미플로(de mi flor)’ 모델로 발탁된 배우 이이담 ...
서울--(뉴스와이어)--환경실천연합회(이하 환실련, 회장 이경율)가 세계 환경의 날을 기념해 ‘제23회 국제 지구사랑 작품공모전’(이하 작품공모전)을 개최한다. 환경실천연합회 제22회 국제 지구사랑 작품공모전 동영상 부문 금상 Down & Out ...
API
fg
유니콘뉴스는 보도자료 배포 서비스입니다.
여기에 뉴스를 등록하면 언론이 보도하고 널리 배포됩니다.